news
-
22-05-2018
FY 2017 Results General Investor Call
Friday 25 May 2018 – 09.00 GMT / 10.00 CET
read more -
27-04-2018
Annual General Meeting of Shareholders 2018
Kedrion’s shareholders approve financial statements for fiscal year 2017, confirm board of directors
read more -
29-03-2018
Annual Results 2017
Consolidated turnover of Euro 602.5 million and adjusted EBITDA of Euro 139.9 million, up 31.6%
read more -
31-01-2018
Opening of an antitrust investigation
read more -
31-10-2017
Kedrion and Cerus enter distribution agreement for INTERCEPT in Italy
Agreement covers complete INTERCEPT product line: platelets, plasma, and red blood cells
read more -
25-08-2017
Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®
The product is approved for post-exposure prophylaxis against rabies infection
read more -
11-08-2017
First half results 2017
First half consolidated turnover of EUR 271.7 M and adjusted EBITDA increase by 29.0% compared to the same period in 2016, with a margin of 24.1%
read more -
12-07-2017
Result of cash tender offer for Notes due 24 april 2019
The Company hereby announces to accept for purchase Notes validly tendered pursuant to the Offer for a total aggregate principal amount equal to €91,080,000
read more -
05-07-2017
Launch of new 350 Million Bond and tender offer indicative results
Kedrion successfully completed pricing of new Euro 350 M notes due July 2022 and tender offer for notes due April 2019
read more -
27-06-2017
Cash Tender Offer for Notes due 24 April 2019
Tender Offer for €300,000,000 4.625 per cent. Notes due 24 April 2019
read more
Where 